General AML,   IDH1/2

Eytan Stein | ASH 2018 | Early results from the Beat AML Master Trial

L:

At the 60th Annual Meeting of the American Society of Hematology, San Diego, US, Eytan Stein from Memorial Sloan Kettering Cancer Center, New York, US, talks about the design and objectives of the Beat AML, a precision medicine trial for previously untreated acute myeloid leukemia (AML) patients age ≥ 60 years. Eytan Stein further discussed the findings of a sub-study of the Beat AML trial which is assessing the efficacy of the oral IDH2 inhibitor enasidenib, in newly diagnosed AML patients age ≥ 60 years with an IDH2 mutation.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative